HNB
RVNC

Huntington National Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

Huntington National Bank’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-175
Closed -$450 – 4228
2024
Q2 		$450 Buy
+175
New +$598 ﹤0.01% 2430
2017
Q3 		– Sell
-236
Closed -$6K – 1673
2017
Q2 		$6K Hold
236
– – ﹤0.01% 1365
2017
Q1 		$5K Sell
236
-43
-15% -$883 ﹤0.01% 1268
2016
Q4 		$6K Buy
279
+30
+12% +$502 ﹤0.01% 1280
2016
Q3 		$4K Buy
+249
New +$3.62K ﹤0.01% 1394

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Huntington National Bank's RVNC Position: Q3 2024 in Review

Huntington National Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 175 shares — an estimated $450 sold.

Huntington National Bank first reported a position in RVNC in Q3 2016 and held it in 5 quarters. The position peaked at $6K in Q2 2017. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Huntington National Bank reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Huntington National Bank sold 175 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $450.
  • Huntington National Bank first reported a position in Revance Therapeutics, Inc. in Q3 2016 and held it in 5 quarters.
  • Huntington National Bank's Revance Therapeutics, Inc. position peaked at $6K in Q2 2017.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Huntington National Bank's 13F filing for Q3 2024, filed 6 Nov 2024.